Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blind Placebo-Controlled Phase II Multi-Center Study of Inflammation Modification of Canakinumab to Prevent Leukemic Progression of Clonal Cytopenias of Unknown Significance (CCUS): IMPACT Study

NCT05641831 is registered in ClinicalTrials.gov with Uma Borate as lead sponsor.

NCT NCT05641831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05641831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blind Placebo-Controlled Phase II Multi-Center Study of Inflammation Modification of Canakinumab to Prevent Leukemic Progression of Clonal Cytopenias of Unknown Significance (CCUS): IMPACT Study
Lead sponsor
Uma Borate
Phase
Phase 2
Overall status
Recruiting
Start date
February 6, 2023
Completion date
December 31, 2028
Enrollment
110 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

clonal cytopenia of undetermined significance